Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Breast Neoplasms 26Triple Negative Breast Neoplasms 13Prostatic Neoplasms 12Ovarian Neoplasms 12Neoplasms 10Neoplasm Metastasis 8Fallopian Tube Neoplasms 6Leukemia, Myeloid, Acute 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Carcinoma, Renal Cell 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2mCRPC 1Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Solid Tumor 1Sarcoma 1

Interventions

Paclitaxel 2Carboplatin 2talazoparib 1olaparib 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Triple Negative Metastatic Breast Cancer × talazoparib × Clear all
NCT02358200 2020-01-10

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

University of California, San Francisco

Phase 1 Terminated
23 enrolled
BreastOther solid neoplasm

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡